Institute of Parasitology, Vetsuisse Faculty, University of Berne, Länggassstrasse 122, CH-3012 Berne, Switzerland.
Institute of Parasitology, Vetsuisse Faculty, University of Berne, Länggassstrasse 122, CH-3012 Berne, Switzerland.
Int J Antimicrob Agents. 2014 Apr;43(4):335-42. doi: 10.1016/j.ijantimicag.2014.01.013. Epub 2014 Feb 12.
The current chemotherapeutic treatment of alveolar echinococcosis (AE) in humans is based on albendazole and/or mebendazole. However, the costs of treatment, life-long consumption of drugs, parasitostatic rather than parasiticidal activity of chemotherapy, and high recurrence rates after treatment interruption warrant more efficient treatment options. Experimental treatment of mice infected with Echinococcus multilocularis metacestodes with fenbendazole revealed similar efficacy to albendazole. Inspection of parasite tissue from infected and benzimidazole-treated mice by transmission electron microscopy (TEM) demonstrated drug-induced alterations within the germinal layer of the parasites, and most notably an almost complete absence of microtriches. On the other hand, upon in vitro exposure of metacestodes to benzimidazoles, no phosphoglucose isomerase activity could be detected in medium supernatants during treatment with any of these drugs, indicating that in vitro treatment did not severely affect the viability of metacestode tissue. Corresponding TEM analysis also revealed a dramatic shortening/retraction of microtriches as a hallmark of benzimidazole action, and as a consequence separation of the acellular laminated layer from the cellular germinal layer. Since TEM did not reveal any microtubule-based structures within Echinococcus microtriches, this effect cannot be explained by the previously described mechanism of action of benzimidazoles targeting β-tubulin, thus benzimidazoles must interact with additional targets that have not been yet identified. In addition, these results indicate the potential usefulness of fenbendazole for the chemotherapy of AE.
目前,人类泡型包虫病(AE)的化学治疗基于阿苯达唑和/或甲苯达唑。然而,治疗费用、药物的终身消耗、化疗的寄生虫静止而非寄生虫杀灭作用以及治疗中断后的高复发率,都需要更有效的治疗选择。用芬苯达唑对感染多房棘球蚴包虫蚴的小鼠进行实验治疗,结果显示其疗效与阿苯达唑相似。用透射电子显微镜(TEM)检查感染和苯并咪唑治疗的小鼠的寄生虫组织,结果表明药物在寄生虫的生发层中引起了改变,最显著的是微绒毛几乎完全缺失。另一方面,在体外将包虫蚴暴露于苯并咪唑类药物时,在任何一种药物的治疗过程中,都无法在培养基上清液中检测到磷酸葡萄糖异构酶活性,这表明体外治疗不会严重影响包虫蚴组织的活力。相应的 TEM 分析还显示,微绒毛的急剧缩短/回缩是苯并咪唑作用的一个标志,并且无细胞的层状层与细胞生发层分离。由于 TEM 未在棘球蚴微绒毛中发现任何基于微管的结构,因此这种作用不能用以前描述的针对β-微管蛋白的苯并咪唑作用机制来解释,因此苯并咪唑类药物必须与尚未确定的其他靶标相互作用。此外,这些结果表明芬苯达唑在泡型包虫病化学治疗中的潜在应用价值。